MedPath

Lymph Node 14v Dissection in Clinical Stage T3N+, T4N+ of Gastric Cancer

Phase 3
Conditions
Gastric Cancer
Interventions
Procedure: D2 lymphadenectomy
Procedure: D2 and #14v lymphadenectomy
Registration Number
NCT03264807
Lead Sponsor
National Cancer Center, Korea
Brief Summary

The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection.

Detailed Description

The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection. Actually, if the 14v lymph node metastasis is suspected before surgery, it is excluded from the study. In a retrospective study conducted in our hospital, we compared the patients with the 14v lymphadenectomy group and those without the 14v lymphadenectomy group, the survival rate of the 14v lymphadenectomy group was 11% higher than that of the 14v non-lymphadenectomy group.Previous studies have suggested that the presence of metastatic lymph nodes in the 14v lymph node is not good and that removal of the 14v lymph node does not affect prognosis. However, if the lymph node is a continuous tissue and the transition to the 14v lymph node is confirmed microscopically, a negative prognosis may be expected because it is likely that the cancer has spread to the distal lymph node. In addition, inadequate resection of the lymphatic or 14v lymph node adjacent to the 14v lymph node in the absence of evidence of metastasis of the 14v lymph node under microscopic examination indicates that cancer may spread even after curative surgery, To prevent cancer metastasis.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
518
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
D2 lymphadenectomyD2 lymphadenectomySubtotal gastrectomy with D2 lymphadnectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) could be performed in this arm
D2 and #14v lymphadenectomyD2 and #14v lymphadenectomySubtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and lymph node #14v lymphadnectomy could be performed in this arm
Primary Outcome Measures
NameTimeMethod
Superiority verification of disease-free survival after lymphadenectomy for D2 + 14v lymph node dissection in gastric resection in patients with T3N + and T4N + stomach cancerthe last recruited patient was followed up for 3 years

Patients were randomized to an intention-to-treat population. The primary efficacy assessment was performed at the end of the 3-year follow-up period. The free-disease survival rates of the two groups were compared by log rank test.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (12)

Dongnam Inst. of Radiological & Medical Sciences

🇰🇷

Busan, Gijang-gun, Korea, Republic of

The Catholic University of Korea, Incheon St. Mary'S Hospital

🇰🇷

Incheon, Bupyeong-gu, Korea, Republic of

National Cancer Center

🇰🇷

Gyeonggi-do, Goyang-si, Korea, Republic of

Dankook University Hospital

🇰🇷

Cheonan, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Songpa-gu, Korea, Republic of

Gyeongsang National University Changwon hospital

🇰🇷

Changwon, Korea, Republic of

A JOU University medical center

🇰🇷

Gyeonggi-do, Suwon-si, Korea, Republic of

Gyeongsang national university hospital

🇰🇷

Gyeongsang, Gingu-si, Korea, Republic of

catholic university of korea,Seoul ST. Mary's Hospital.

🇰🇷

Seocho, Seoul, Korea, Republic of

Pusan National University Yangsan Hospital

🇰🇷

Gyeongsang, Yangsan-si, Korea, Republic of

Severance Hospital

🇰🇷

Seoul, Sincon, Korea, Republic of

The CATHOLIC University of KOREA, INCHEON ST.MARY's hospital

🇰🇷

Incheon, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath